Share Name Share Symbol Market Type Share ISIN Share Description
Synairgen Plc LSE:SNG London Ordinary Share GB00B0381Z20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 13.50p 13.00p 14.00p 13.50p 13.50p 13.50p 5,794 07:46:32
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.0 1.6 1.9 7.0 12.33

Synairgen Share Discussion Threads

Showing 751 to 775 of 775 messages
Chat Pages: 31  30  29  28  27  26  25  24  23  22  21  20  Older
DateSubjectAuthorDiscuss
15/6/2018
18:21
I bought another 40k this week after waiting for the offer to drop below 14p.My largest holding by a country mile.
ohisay
15/6/2018
13:20
With the results coming in the next quarter I think this will be the next biotech to take off. The chance of a positive result is high and if so, the market cap is ridiculous. Fibrosis is just about the hottest area in Pharma at the moment so assuming good results, they will be queuing up to license this drug! I already have a good sized position but will be buying more in the next month or so. Nobby
nobbygnome
15/6/2018
12:37
Interesting article on the race to get an effective NASH treatment by European biotechs. https://labiotech.eu/nash-liver-disease-europe/
ohisay
14/6/2018
09:56
http://www.pharmaxis.com.au/assets/Documents/pdf/02018/ASX/2018-06-14-LOXL2-BIO18-Update.pdf
ohisay
14/6/2018
07:15
Media Release        14 June 2018 PHARMAXIS ‘BEST IN CLASS’ LOXL2 PROGRAM ATTRACTS STRONG PHARMA INTEREST AS IT ENTERS FINAL STAGE OF PHASE 1 TRIALS  First stage of phase 1 studies demonstrate a best in class profile for lysyl oxidase like 2 (LOXL2) inhibitors with two compounds achieving significant and long lasting inhibition of LOXL2 enzyme after a single oral dose.  Final stages of phase 1 studies and phase 2 enabling toxicity studies are due to complete in Q3 2018.    Pharmaxis conducts multiple partnering discussions with multinational Pharma companies at BIO 2018
rosejs2
30/5/2018
11:30
>> timbo I will try to join you at the AGM. I am considering building a very large position here because it look so ridiculously undervalued. You are due a belated thanks from me for the heads up about this company! Nobby
nobbygnome
30/5/2018
11:20
The AGM is on 22nd June, so I will go along to that as Billy no mates (once again), to hear what is going on.
timbo003
30/5/2018
11:05
Indeed .COPD safety study due first I think. Worth recalling the House broker view ... Broker FinnCap reckons the stock is worth 35p based on a discounted cash flow (DCF) valuation that that puts 17p and 18p a share price tags on, respectively, SNG001 and LOXL2. This DCF valuation will rise to £41mln, or 45p a share following the successful completion of a pilot safety study of SNG001
ohisay
30/5/2018
10:26
I think SNG will be the next small cap biotech to take off. There are various trial results coming very shortly so I think the next couple of months could be very interesting..... Nobby
nobbygnome
30/5/2018
09:31
http://www.proactiveinvestors.co.uk/companies/news/197899/astrazeneca-chalks-up-another-phase-iii-fail-as-copd-drug-misses-target (LON:AZN) rather patchy success rate for late-stage clinical trials continued after its drug Fasenra failed to show a statistically significant impact on people suffering exacerbations of moderate to very severe chronic obstructive pulmonary disease (COPD). The top-line results from the TERRANOVA phase III study followed the announcement earlier this month that another final-phase assessment of the treatment, called, GALATHEA, had drawn a blank. Chief medical officer Dr Sean Bohen said: "These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options. Marsden has said its not impossible that AZN will come back for COPD - first part of SNG trial results due this quarter of course.
ohisay
23/5/2018
20:31
Latest SNG Corporate Presentation March 2018 hxxp://www.synairgen.com/media/1378/synairgen-march-2018-21_03_18.pdf
rosejs2
22/5/2018
10:10
Great interview, refreshing to listening to someone passionate and informative as opposed to the normal management speak full of soundbites.
auphilman
22/5/2018
02:37
https://www.youtube.com/embed/K_WBCeIYD-s 4 minutes in on LOXL - quite compelling ..
ohisay
15/5/2018
07:28
http://www.proactiveinvestors.com.au/companies/stocktube/9289/pharmaxis-has-key-drivers-in-place-for-short-and-long-term-value-creation-9289.html
ohisay
01/5/2018
06:58
Nice summary from somebody who's just twigged SNG is cheap. https://twitter.com/RichTheNewbie Headline notes on my recent punt in case anyone is interested (Synairgen - LON:SNG): https://pbs.twimg.com/media/DcB0U_zW0AAGVoO.jpg:large
ohisay
30/4/2018
08:24
http://www.proactiveinvestors.com.au/companies/news/196009/pharmaxis-boosts-cash-position-securing-sustainable-future-196009.html
ohisay
30/4/2018
03:02
https://www.youtube.com/watch?v=9sa2WZiNPdA&feature=youtu.be&a= PXS quarterly out - see 3.30 in for LOXL developments- so far so good...
ohisay
24/4/2018
02:15
Just a reminder about Pharmaxis and Synairgen LOXL 2 milestones this year. http://www.pharmaxis.com.au/assets/Documents/pdf/02018/Other/2018-02-05-Bioshares-730-PXS.pdf Biotech is bubbling again with a swag of locally based takeovers and rising share prices. Pharmaxis in particular has been successful in getting the interest of big pharma. https://twitter.com/search?f=news&vertical=default&q=pharmaxis%20&src=typd
ohisay
18/4/2018
16:03
Cash at immu is 7p a share i think. Here it is 7p too. Knowing Immu I would sell it at 35p and buy here for sure. The science is credible, backed by practicing doctors and a third party Pharmaxis has paid upfront in the belief it can sell onwards one of the drugs. IP havent helped this company but hopefully Pharmaxis will.
allonblack
18/4/2018
15:07
Have to say that ,not for the first time, small pharma market valuations can get well beyond themselves in terms of EV.IMM more than £200m pre results - SNG not much more thsn £5m . IMV there could be never ever be any kind of accounting for this difference even on a risked evaluation .Mr Market is often comprehensively wrong.
ohisay
16/4/2018
16:42
We now have an answer to Part 1 of my question .. Leonard Licht, a private investor, now holds 6,650,000 ordinary shares of 1 pence each in the capital of the Company through his Choice Bespoke SIPP. This represents 7.27% of the total voting rights of the Company.
rosejs2
13/4/2018
20:54
ohisay...fully agree with your observations.. Other than the 3rd April 18 notification of the increase in Leonard Lichts holding.. there has been no notifications of either a reduction in A holding or information regarding an increase in an existing holding.....With some large value sells and likewise large value buys.. I am curious who has sold and importantly who has been buying.. A new major holder might surface !!! perhaps next week we may find the answer to this question..
rosejs2
13/4/2018
17:36
Seems like MMs willing to sell plenty at 12.5 knowing there are willing buyers at 13p plus - just an observation ..
ohisay
22/3/2018
01:42
Interesting Timbo - many thanks
ohisay
21/3/2018
14:00
a short addendum.... RM used the term "dance together" repeatedly when describing the interaction between virus and the bacteria in COPD exacerbations and said it was most apparent between non-typeable Haemophilus influenzae (NTHi) bacteria and human rhinovirus (HRV), although I note that the FILMARRAY is not specific for Haemophilus influenzae and I don't know whether it detects that infection as well as HRV.
timbo003
Chat Pages: 31  30  29  28  27  26  25  24  23  22  21  20  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20180618 00:08:40